Search - tctmd.com

Displaying 241 - 260 of 392

Sort: Relevancy | Date

News Industry News

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

May 06, 2014

News Industry News

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

May 01, 2014

News Daily News

Registro FAST-MI: La Fibrinolisis y la PCI, Primaria arrojan una Supervivencia Similar a los 5 Años en Pacientes STEMI

L.A. McKeown

April 03, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

News Conference News ACC 2014

EUROMAX: Bivalirudin May Hold Key to Solving Problem of Early ST After Primary PCI

Jason Kahn

March 29, 2014

News Industry News

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

March 27, 2014

News Daily News

HORIZONS-AMI: El Daño Renal Durante una PCI Primaria está Estrechamente asociado al Pronóstico

March 20, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

News Daily News

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Yael L. Maxwell

February 13, 2014

News Daily News

Las Hemorragias son Frecuentes aunque No Suelen hacerse Públicas en Pacientes SCA a Tratamiento Antiplaquetario

L.A. McKeown

February 06, 2014

News Daily News

Transradial Approach May Balance Bleeding Benefits of Bivalirudin in Primary PCI

Jason Kahn

January 15, 2014

News Daily News

El Abordaje Transradial podría Equilibrar los Beneficios Hemorrágicos de la Bivalirudina en las PCI Primarias

Jason Kahn

January 15, 2014

News Daily News

La PCI Primaria Reduce los Síntomas frente a la Fibrinolisis 5 Años después de un Cuadro de STEMI

L.A. McKeown

January 01, 2014

News Industry News

Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System

December 05, 2013

News Conference News AHA 2013

Long-term Outcomes with Renal Denervation Show Sustained Benefit

Yael L. Maxwell

November 16, 2013

News Daily News

研究结果支持ACS患者的DAPT治疗持续3个月以上

L.A. McKeown

November 01, 2013

News Daily News

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

L.A. McKeown

November 01, 2013

News Conference News TCT 2013

Thrombectomy Fails to Reduce Microvascular Obstruction in Non-STEMI

October 31, 2013

News Conference News TCT 2013

Second-Generation TAVR Device Overcomes Issues of Current Valves

October 31, 2013

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

Advertisement

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

Registro FAST-MI: La Fibrinolisis y la PCI, Primaria arrojan una Supervivencia Similar a los 5 Años en Pacientes STEMI

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

EUROMAX: Bivalirudin May Hold Key to Solving Problem of Early ST After Primary PCI

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

HORIZONS-AMI: El Daño Renal Durante una PCI Primaria está Estrechamente asociado al Pronóstico

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Las Hemorragias son Frecuentes aunque No Suelen hacerse Públicas en Pacientes SCA a Tratamiento Antiplaquetario

Transradial Approach May Balance Bleeding Benefits of Bivalirudin in Primary PCI

El Abordaje Transradial podría Equilibrar los Beneficios Hemorrágicos de la Bivalirudina en las PCI Primarias

La PCI Primaria Reduce los Síntomas frente a la Fibrinolisis 5 Años después de un Cuadro de STEMI

Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System

Long-term Outcomes with Renal Denervation Show Sustained Benefit

研究结果支持ACS患者的DAPT治疗持续3个月以上

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

Thrombectomy Fails to Reduce Microvascular Obstruction in Non-STEMI

Second-Generation TAVR Device Overcomes Issues of Current Valves

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content